AstraZeneca (NYSE:AZN) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Thursday.
AZN has been the topic of several other reports. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group reissued a “buy” rating on shares of AstraZeneca in a research report on Sunday, December 9th. UBS Group reissued a “hold” rating on shares of AstraZeneca in a research report on Monday, November 19th. BMO Capital Markets reissued a “buy” rating and set a $48.00 price target on shares of AstraZeneca in a research report on Tuesday, January 15th. Finally, Goldman Sachs Group reissued a “sell” rating on shares of AstraZeneca in a research report on Friday, November 16th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $45.50.
Shares of NYSE AZN opened at $40.92 on Thursday. AstraZeneca has a 12 month low of $32.69 and a 12 month high of $41.78. The firm has a market cap of $103.65 billion, a PE ratio of 9.56, a P/E/G ratio of 1.94 and a beta of 0.51. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.86 and a quick ratio of 0.66.
AstraZeneca (NYSE:AZN) last announced its earnings results on Thursday, February 14th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.73 by $0.85. AstraZeneca had a return on equity of 27.32% and a net margin of 11.29%. The business had revenue of $6.42 billion during the quarter, compared to the consensus estimate of $6.33 billion. During the same period in the prior year, the business posted $1.30 earnings per share. AstraZeneca’s revenue was up 11.1% compared to the same quarter last year. On average, research analysts anticipate that AstraZeneca will post 1.64 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. Primecap Management Co. CA increased its position in AstraZeneca by 4.5% in the 3rd quarter. Primecap Management Co. CA now owns 55,399,286 shares of the company’s stock worth $2,192,150,000 after purchasing an additional 2,364,013 shares during the last quarter. Jennison Associates LLC increased its position in AstraZeneca by 15.2% in the 4th quarter. Jennison Associates LLC now owns 45,796,787 shares of the company’s stock worth $1,739,362,000 after purchasing an additional 6,052,483 shares during the last quarter. FMR LLC increased its position in AstraZeneca by 74.5% in the 3rd quarter. FMR LLC now owns 35,325,790 shares of the company’s stock worth $1,397,841,000 after purchasing an additional 15,082,609 shares during the last quarter. Fisher Asset Management LLC increased its position in AstraZeneca by 10.7% in the 4th quarter. Fisher Asset Management LLC now owns 14,965,240 shares of the company’s stock worth $568,380,000 after purchasing an additional 1,448,516 shares during the last quarter. Finally, Capital International Investors increased its position in AstraZeneca by 3.4% in the 3rd quarter. Capital International Investors now owns 9,752,587 shares of the company’s stock worth $385,910,000 after purchasing an additional 319,416 shares during the last quarter. 17.27% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Penny Stocks, What You Need To Know
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.